

Full search Strategy for Meta-analysis of Trastuzumab Deruxtecan (T-DXd) for GI cancer

Pubmed search 1163 results on 2/22/2024

("Digestive system neoplasms"[Mesh] OR ((gastrointestinal[tiab] OR stomach[tiab] OR gastric[tiab] OR biliary[tiab] OR "bile duct"[tiab] OR colon*[tiab] OR colorect*[tiab] OR intestin*[tiab] OR anus*[tiab] OR anal[tiab] OR bowel[tiab] OR rect*[tiab] OR liver*[tiab] OR hepat*[tiab] OR pancreas*[tiab] OR esophag*[tiab] OR oesophag*[tiab] OR "gastroesophageal junction"[tiab] OR "gastro-oesophageal junction"[tiab])) AND (neoplas*[tiab] OR cancer*[tiab] OR carcinoma*[tiab] OR adenocarcinoma*[tiab] OR tumor*[tiab] OR tumour*[tiab] OR malignan*[tiab]))) AND ("Trastuzumab"[Mesh] OR "trastuzumab deruxtecan" [Supplementary Concept] OR "Immunoconjugates"[Mesh] OR "Immunoconjugates"[Pharmacological Action] OR "Trastuzumab deruxtecan"[tiab] OR DS-8201[tiab] OR DS-8201a[tiab] OR Famtrastuzumab[tiab] OR "fam-trastuzumab deruxtecan-nxki"[tiab] OR TraD[tiab] OR trastuzumabderuxtecan[tiab] OR ((HER2[tiab] OR "human epidermal growth factor receptor 2"[tiab]) AND ("antibody-drug conjugat*" [tiab] OR "antibody drug conjugat*" [tiab])) OR enhertu[tiab] OR T-DXd[tiab] OR "immunoconjugat*" [tiab] OR Radioimmunoconjugate*[tiab]) AND ("Dose-Response Relationship, Drug"[MeSH] OR "Maximum Tolerated Dose"[Mesh] OR "adverse effects"[subheading] OR "Drug-Related Side Effects and Adverse Reactions"[Mesh] OR toxic*[tiab] OR advers*[tiab] OR "dose-response relationship"[tiab] OR Safe*[tiab] OR Tolera*[tiab] OR efficacy[tiab] OR Recommend*[tiab] OR reaction*[tiab] OR "side effect*" [tiab] OR "drug event*" [tiab] OR contraindication*[tiab] OR Optimiz*[tiab] OR Respon*[tiab] OR Effective*[tiab] OR ineffective*[tiab]) AND (2015/1/1:3000/12/12[mdat]))

Embase

Unchecked all mapping

4913 results 2/22/2024

('digestive system tumor'/exp OR ((gastrointestinal:ti,ab OR stomach:ti,ab OR gastric:ti,ab OR biliary:ti,ab OR 'bile duct':ti,ab OR colon*:ti,ab OR colorect*:ti,ab OR intestin*:ti,ab OR anus*:ti,ab OR anal:ti,ab OR bowel:ti,ab OR rect*:ti,ab OR liver*:ti,ab OR hepat*:ti,ab OR pancreas*:ti,ab OR esophag*:ti,ab OR oesophag*:ti,ab OR 'gastroesophageal junction':ti,ab OR 'gastro-oesophageal junction':ti,ab) AND (neoplas*:ti,ab OR cancer*:ti,ab OR carcinoma*:ti,ab OR adenocarcinoma*:ti,ab OR tumor*:ti,ab OR tumour*:ti,ab OR malignan*:ti,ab))) AND (Trastuzumab/exp OR 'trastuzumab deruxtecan'/exp OR 'Trastuzumab deruxtecan':ti,ab OR DS-8201:ti,ab OR DS-8201a:ti,ab OR Famtrastuzumab:ti,ab OR 'fam-trastuzumab deruxtecan-nxki':ti,ab OR TraD:ti,ab OR trastuzumabderuxtecan:ti,ab OR ((HER2:ti,ab OR 'human epidermal growth factor receptor 2':ti,ab OR 'epidermal growth factor receptor 2'/exp) AND ('antibody conjugate'/exp OR 'antibody-drug conjugat*':ti,ab OR 'antibody drug conjugat*':ti,ab)) OR enhertu:ti,ab OR T-DXd:ti,ab OR immunoconjugat*:ti,ab OR Radioimmunoconjugate*:ti,ab) AND ('dose response'/exp OR 'Maximum Tolerated Dose'/exp OR 'adverse drug reaction'/exp OR toxic*:ti,ab OR advers*:ti,ab OR 'dose-response relationship':ti,ab OR Safe*:ti,ab OR Tolera*:ti,ab OR efficacy:ti,ab OR Recommend*:ti,ab OR reaction*:ti,ab OR 'side effect*':ti,ab OR 'drug event*':ti,ab OR contraindication*:ti,ab OR Optimiz*:ti,ab OR Respon*:ti,ab OR Effective*:ti,ab OR ineffective*:ti,ab) AND [2015-3000]/py

Cochrane

Unchecked map to subject heading

512 results 2/22/2024

(exp "Digestive system neoplasms"/ OR ((gastrointestinal.ti,kw,ab. OR stomach.ti,kw,ab. OR gastric.ti,kw,ab. OR biliary.ti,kw,ab. OR "bile duct".ti,kw,ab. OR colon*.ti,kw,ab. OR colorect*.ti,kw,ab. OR intestin*.ti,kw,ab. OR anus*.ti,kw,ab. OR anal.ti,kw,ab. OR bowel.ti,kw,ab. OR rect*.ti,kw,ab. OR liver*.ti,kw,ab. OR hepat*.ti,kw,ab. OR pancreas*.ti,kw,ab. OR esophag*.ti,kw,ab. OR oesophag*.ti,kw,ab. OR "gastroesophageal junction".ti,kw,ab. OR "gastro-oesophageal junction".ti,kw,ab.) AND (neoplas*.ti,kw,ab. OR cancer*.ti,kw,ab. OR carcinoma*.ti,kw,ab. OR adenocarcinoma*.ti,kw,ab. OR tumor*.ti,kw,ab. OR tumour*.ti,kw,ab. OR malignan*.ti,kw,ab.))) AND (exp Trastuzumab/ OR term.hw. OR exp Immunoconjugates/ OR "Trastuzumab deruxtecan".ti,kw,ab. OR DS-8201.ti,kw,ab. OR DS-8201a.ti,kw,ab. OR Famtrastuzumab.ti,kw,ab. OR "fam-trastuzumab deruxtecan-nxki".ti,kw,ab. OR TraD.ti,kw,ab. OR trastuzumabderuxtecan.ti,kw,ab. OR ((HER2.ti,kw,ab. OR "human epidermal growth factor receptor 2".ti,kw,ab.) AND ("antibody-drug conjugat*".ti,kw,ab. OR "antibody drug conjugat*".ti,kw,ab.)) OR enhertu.ti,kw,ab. OR T-DXd.ti,kw,ab. OR immunoconjugat*.ti,kw,ab. OR Radioimmunoconjugate*.ti,kw,ab.) AND (exp "Dose-Response Relationship, Drug"/ OR exp "Maximum Tolerated Dose"/ OR exp "Drug-Related Side Effects and Adverse Reactions"/ OR toxic*.ti,kw,ab. OR advers*.ti,kw,ab. OR "dose-response relationship".ti,kw,ab. OR Safe*.ti,kw,ab. OR Tolera*.ti,kw,ab. OR efficacy.ti,kw,ab. OR Recommend*.ti,kw,ab. OR reaction*.ti,kw,ab. OR "side effect*".ti,kw,ab. OR "drug event*".ti,kw,ab. OR contraindication*.ti,kw,ab. OR Optimiz*.ti,kw,ab. OR Respon*.ti,kw,ab. OR Effective*.ti,kw,ab. OR ineffective*.ti,kw,ab.)

Then limit to 2015-current

Clinicaltrials.gov

Disease: Digestive system neoplasms

Intervention: (Trastuzumab deruxtecan OR DS-8201 OR DS-8201a OR Famtrastuzamab OR TraD OR T-DXd)